[144] Charles River Laboratories International, Inc. SEC Filing

Rhea-AI Filing Summary

Charles River Laboratories (CRL) Form 144 shows a proposed sale of 400 shares of common stock to be executed through UBS Financial Services on 08/22/2025 with an indicated aggregate market value of $61,000. The securities were originally acquired on 01/27/2023 as Performance Stock Units from Charles River Laboratories, with 8,379 units reported as acquired and payment in cash on 05/13/2025. The filer also reported two recent sales in August 2025: 800 shares sold on 08/18/2025 for $126,054 and 400 shares sold on 08/08/2025 for $5,991. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.

Positive

• Regulatory compliance: The filer provided required Form 144 disclosures including broker, acquisition details, and recent sales.
• Transparency: The filing specifies acquisition type (Performance Stock Units) and payment method (cash).

Negative

• Insider selling: Proposed sale of 400 shares and recent August disposals totaling 1,200 shares indicate insider share liquidation activity.

Insights

Securities Analyst

TL;DR: Insider filing discloses a small planned sale and recent August transactions; appears routine and regulatory-compliant.

The Form 144 notifies the market of a proposed disposal of 400 common shares through UBS on 08/22/2025 with an aggregate market value of $61,000. The underlying shares were acquired as Performance Stock Units on 01/27/2023, with payment recorded in cash on 05/13/2025. Two prior August sales are disclosed totaling 1,200 shares. From a trading-impact perspective, these volumes are modest relative to typical public float sizes and the filing serves primarily as regulatory transparency rather than signaling a material corporate change.

Corporate Governance Expert

TL;DR: Filing documents insider dispositions and affirms no undisclosed material information; governance process appears followed.

The notice contains the required certifications and transaction detail for compliance with Rule 144, including acquisition origin (Performance Stock Units) and broker information (UBS Financial Services). The signer represents no knowledge of undisclosed adverse information and the form includes recent prior sales in August 2025. This record aligns with standard disclosure expectations for officer or affiliate share dispositions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	400	61000	49120000	08/22/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/27/2023	Performance Stock Unit	Charles River Laboratories			8379	05/13/2025	cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Joseph LaPlume c/o Charles River Laboratories, 251 Ballardvale Street Wilmington MA 01887	common	08/18/2025	800	126054
Joseph LaPlume c/o Charles River Laboratories 251 Ballardvale Street Wilmington MA 01887	Common	08/08/2025	400	5991

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does CRL Form 144 report?

The filing reports a proposed sale of 400 common shares of Charles River Laboratories to be sold via UBS on 08/22/2025 with an aggregate market value of $61,000.

How were the shares being sold acquired?

The shares were acquired on 01/27/2023 as Performance Stock Units from Charles River Laboratories; 8,379 units were recorded as acquired and payment was cash on 05/13/2025.

Has the filer sold other CRL shares recently?

Yes; the filing discloses two sales in August 2025: 800 shares on 08/18/2025 for $126,054 and 400 shares on 08/08/2025 for $5,991.

Through which broker will the proposed sale be executed?

The proposed sale is to be executed through UBS Financial Services Inc at the address listed in the filing.

Does the filer assert any undisclosed material information?

The filer represents by signing the notice that they do not know of any material adverse information about the issuer that has not been publicly disclosed.